Key facts
- NOVOS’s last known valuation is $11.2M (Oct 2021).
- It has raised $3.6M; the latest was Later Stage VC in Mar 2026.
- Notable investors include Resolute Ventures, Neman Ventures, Unilever Ventures, Cornucopian Capital, Jerome Ternynck — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for NOVOS
- ·The full record, as it builds
Funding rounds
No funding rounds for NOVOS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NOVOS
Provider of healthcare drink supplement enriched with anti-aging and longevity qualities intended to improve mental health and wellness. The company's products include nicotinamide riboside, magnesium, fisetin, and pterostilbene, as well as antioxidants and other functional ingredients that improve DNA repair and reduce DNA damage, allowing consumers to expand their lifespan and improve their health.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2018
- Employees
- 32
- Website
- novoslabs.com/
- Ownership
- Privately Held (backing)
NOVOS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NOVOS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NOVOS in its N-PORT filings yet. We sweep new filings monthly.